Publicaciones en las que colabora con Eva Bandrés Elizalde (22)

2021

  1. Delta-24-RGD, an oncolytic adenovirus, increases survival and promotes proinflammatory immune landscape remodeling in models of AT/RT and CNS-PNET

    Clinical Cancer Research, Vol. 27, Núm. 6, pp. 1807-1820

2020

  1. Assessment of minimal residual disease by next generation sequencing in peripheral blood as a complementary tool for personalized transplant monitoring in myeloid neoplasms

    Journal of Clinical Medicine, Vol. 9, Núm. 12, pp. 1-20

2014

  1. MiRNA cargo within exosome-like vesicle transfer influences metastatic bone colonization

    Molecular Oncology, Vol. 8, Núm. 3, pp. 689-703

2013

  1. MiR-326 associates with biochemical markers of bone turnover in lung cancer bone metastasis

    Bone, Vol. 52, Núm. 1, pp. 532-539

  2. MicroRNAs in colorectal cancer

    MicroRNAs in Cancer (CRC Press), pp. 177-219

2011

  1. Association of RRM1 -37A>C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapy

    European Journal of Cancer, Vol. 47, Núm. 6, pp. 839-847

  2. Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas

    PLoS ONE, Vol. 6, Núm. 10

  3. MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells

    Stem Cells, Vol. 29, Núm. 11, pp. 1661-1671

2010

  1. Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients

    British Journal of Cancer, Vol. 103, Núm. 10, pp. 1529-1535

  2. EVI1 controls proliferation in acute myeloid leukaemia through modulation of miR-1-2

    British Journal of Cancer, Vol. 103, Núm. 8, pp. 1292-1296

  3. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): A dose-finding study and pharmacogenomic analysis

    British Journal of Cancer, Vol. 102, Núm. 6, pp. 987-994

  4. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia

    Blood, Vol. 115, Núm. 3, pp. 615-625

2009

  1. Epigenetic regulation of MicroRNAs in acute lymphoblastic leukemia

    Journal of Clinical Oncology, Vol. 27, Núm. 8, pp. 1316-1322

  2. Epigenetic regulation of microRNA expression in colorectal cancer

    International Journal of Cancer, Vol. 125, Núm. 11, pp. 2737-2743

  3. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia

    Cancer Research, Vol. 69, Núm. 10, pp. 4443-4453

  4. Pharmacogenomic analysis of the triplet combination of gemcitabine, oxaliplatin and cetuximab as salvage therapy for metastatic colorectal cancer (mCRC) patients

    EJC SUPPLEMENTS

  5. microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells

    Clinical Cancer Research, Vol. 15, Núm. 7, pp. 2281-2290

2008

  1. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth

    Molecular Cancer Research, Vol. 6, Núm. 12, pp. 1830-1840

2007

  1. Erratum: JAK2-V617F activating mutation in acute myeloid leukemia: Prognostic impact and association with other molecular markers (Leukemia (2007) vol. 21 (2386-2390) 10.1038/sj.leu.2404812)

    Leukemia

  2. JAK2-V617F activating mutation in acute myeloid leukemia: Prognostic impact and association with other molecular markers [15]

    Leukemia